WO2020039480A1 - 新規ポリ硫酸ペントサンナトリウム製剤 - Google Patents
新規ポリ硫酸ペントサンナトリウム製剤 Download PDFInfo
- Publication number
- WO2020039480A1 WO2020039480A1 PCT/JP2018/030666 JP2018030666W WO2020039480A1 WO 2020039480 A1 WO2020039480 A1 WO 2020039480A1 JP 2018030666 W JP2018030666 W JP 2018030666W WO 2020039480 A1 WO2020039480 A1 WO 2020039480A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- freeze
- pentosan polysulfate
- sodium
- buffer
- dried preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Definitions
- the present invention relates to a freeze-dried preparation of pentosan polysulfate.
- Sodium pentosan polysulfate is a semi-synthetic compound obtained by chemically modifying polysaccharides extracted from European beech and was first developed in Germany as an anticoagulant, but is now used in the treatment of interstitial cystitis Liquid injections (SP54 (registered trademark)) and oral capsules (Elmilon (registered trademark)) are marketed as drugs.
- SP54 registered trademark
- Elmilon registered trademark
- sodium pentosan polysulfate has a therapeutic effect on arthritis (Non-Patent Document 1).
- freeze-dried preparations of pentosan polysulfate have not been known.
- the present inventors have been developing a therapeutic agent for human arthritis using an injection of pentosan polysulfate.
- pentosan polysulfate for treatment of human arthritis, fine particles due to delamination are generated. That the problem arises.
- injections of pentosan polysulfate have been used for more than 30 years, no such finding has been obtained so far. Therefore, an object of the present invention is to prevent the occurrence of delamination in pentosan polysulfate injection.
- the present inventors thought that by using pentosan sodium polysulfate as a freeze-dried preparation, delamination of an injection of pentosan polysulfate could be prevented, and as a result of conducting various studies on a freeze-dried preparation and its production method, for the first time, The present inventors have succeeded in producing a freeze-dried preparation of pentosan polysulfate, and have found that delamination does not occur even when the freeze-dried preparation is reconstituted, thereby completing the present invention.
- the present invention relates to a lyophilized formulation containing pentosan polysulfate.
- pentosan polysulfate is a polysaccharide having a weight average molecular weight of 1,000 to 6,000 daltons or 1500 to 6,000 daltons having a 1-4-linked ⁇ -D-xylanopyranose unit as a basic skeleton.
- pentosan polysulfate is represented by the following formula:
- R 1 and R 2 represent SO 3 H.
- pentosan polysulfate can be an acetyl-substituted 1-4-bonded ⁇ -D-xylanopyranose group in which the number of n is approximately 1 to 3 to 15 and R 2 is represented by the following formula: .
- sodium pentosan polysulfate in the above formula is such that, on average, one R 2 per 3 to 15 (preferably 6 to 12, preferably 8 to 10) n is represented by the following formula: It may contain a polysaccharide that is an acetyl-substituted 1-4-linked ⁇ -D-xylanopyranose group represented by the formula:
- Pentosan polysulfate is available from Merck Index, 11th Edition, Merck & Co, Inc. , ⁇ Rahway, @N. J. (1989), pp.7093; U.S. Patent Nos. 5,180,715 and 5,643,892; and U.S. Patent Publication 2001/0034328.
- the pentosan polysulfate of the present invention has a sulfate group, it can form a salt with a base. Therefore, the pentosan polysulfate of the present invention may be a pharmacologically acceptable salt of pentosan polysulfate.
- “Pharmacologically acceptable salt” is a salt formed by combining the pentosan polysulfate of the present invention with an inorganic or organic base, and a salt acceptable for administration to the body as a medicament. That is. Such salts are described, for example, in Berge et al. Pharm. Sci. 66: 1-19 (1977).
- Salts include, for example, alkali metal and alkaline earth metal salts such as zinc, lithium, sodium, potassium, magnesium, calcium, silver, lead, copper, gold, palladium, barium; ammonia, methylamine, dimethylamine, trimethylamine, Amines such as dicyclohexylamine, tris (hydroxymethyl) aminomethane, N, N-bis (hydroxyethyl) piperazine, 2-amino-2-methyl-1-propanol, ethanolamine, N-methylglucamine and L-glucamine Salts; and salts with basic amino acids such as lysine, ⁇ -hydroxylysine, and arginine.
- Specific examples include sodium pentosan polysulfate, calcium pentosan polysulfate, and potassium pentosan polysulfate, and preferably sodium pentosan polysulfate.
- the amount of pentosan sodium polysulfate contained in the freeze-dried preparation of the present invention is not particularly limited as long as the reconstituted aqueous preparation can achieve desired safety and effects.
- the lyophilized preparation of the present invention may have a concentration at reconstitution of 80 to 120 mg / mL, preferably 90 to 110 mg / mL, 95 to 105 mg / mL, or 100 mg / mL.
- Sodium (in the formula (I), R 1 and R 2 represent SO 3 Na).
- the freeze-dried preparation of the present invention preferably contains a buffer.
- buffer refers to a substance that plays a role in adjusting the pH to a target value when the lyophilized preparation of the present invention is reconstituted, and that can be administered to mammals as a pharmaceutical.
- the buffer include, but are not limited to, borate buffer (containing sodium borate and sodium hydroxide), phosphate buffer (including sodium dihydrogen phosphate and disodium hydrogen phosphate).
- Carbonate-bicarbonate buffer (containing sodium carbonate and sodium bicarbonate), citrate buffer (containing sodium citrate and citric acid), acetate buffer (containing acetic acid and sodium acetate), succinate buffer Agents, histidine buffer, tartaric acid buffer, HBSS, tris (hydroxymethyl) aminomethane, THAM, citrate / phosphate buffer, barbital buffer, Britton-Robinson buffer, cacodylate buffer, Collidine buffer, formate buffer, maleic acid Buffer, McIlvine buffer, Prideaux-Ward buffer, citric acid-phosphate-borate buffer (Teorell-Stanhagen buffer), veronal acetate buffer, MES (2- (N-morpholino) ethanesulfonic acid) buffer Agent, BIS-TRIS (bis (2-hydroxyethyl) iminotris (hydroxymethyl) methane) buffer, ADA (N- (2-acetamido) -2-iminodiacetic acid) buffer, ACES (N- (N
- the amount of the buffer contained in the freeze-dried preparation of the present invention is not particularly limited as long as the reconstituted aqueous preparation can achieve the desired safety and effect.
- the lyophilized formulation of the present invention has a pH upon reconstitution of 4.8-7.4, 5.0-7.2, 5.0-7.0, or 5.2-7.0.
- a buffer is contained so that
- the concentrations at the time of reconstitution are 0.43 to 1.3, 0.5 to 1.2, and 0.6 to 1.1, respectively. , 0.7 to 1.0, or 0.87 mg / mL, and 2.6 to 7.9, 3 to 7, 4 to 6, 5.0 to 5.5, or 5.26 mg / mL
- it can contain disodium hydrogen phosphate and sodium dihydrogen phosphate.
- the freeze-dried preparation of the present specification contains a pH adjuster as necessary.
- the pH adjuster include potassium hydroxide, sodium hydroxide, lactic acid, hydrochloric acid, adipic acid, aqueous ammonia, dry sodium carbonate, dilute hydrochloric acid, citric acid hydrate, sodium citrate hydrate, and sodium dihydrogen citrate.
- the freeze-dried preparation of the present invention may contain a cryoprotectant in order to further maintain stability, but may not contain such a cryoprotectant.
- a cryoprotectant such as sugars (eg, maltose or mannitol)
- sugars for example, maltose and mannitol
- the lyophilized preparation of the present invention has a concentration of 80 to 120 mg / mL (preferably 90 to 110 mg / mL, 95 to 105 mg / mL, or 100 mg / mL) sodium pentosan sulfate at the time of reconstitution. It contains 1-4 mg / mL disodium hydrogen phosphate decahydrate and 4.5-9.0 mg / mL sodium dihydrogen phosphate dihydrate. More preferably, the lyophilized formulation of the present invention has a concentration at reconstitution of 100 mg / mL sodium pentosan polysulfate, 2.2 mg / mL disodium hydrogen phosphate decahydrate, and 6.84 mg / mL.
- the freeze-dried preparation of the present invention comprises sodium pentosan polysulfate: disodium hydrogen phosphate dodecahydrate: sodium dihydrogen phosphate dihydrate in a mass ratio of 800 to 1200: 16 to 32:32 to 104, Alternatively, it may be contained at a mass ratio of 1000: 22: 68.4.
- the freeze-dried preparation of the present invention comprises a sodium pentosan polysulfate: disodium hydrogen phosphate: sodium dihydrogen phosphate mass ratio of 800 to 1200: 6 to 12:24 to 80, or 1000: 8.72: 52. May be contained at a mass ratio of 0.6.
- the freeze-dried preparation of the present invention can be produced by freeze-drying an aqueous solution containing additives such as sodium pentosan polysulfate and a buffer.
- Sodium pentosan polysulfate can be obtained by reacting xylan extracted from the bark of a plant such as beech with a sulfating agent such as chlorosulfonic acid or sulfuric acid chloride to form a sulfuric ester, followed by sodium hydroxide treatment.
- a sulfating agent such as chlorosulfonic acid or sulfuric acid chloride
- sodium pentosan polysulfate can be produced in consideration of U.S. Patent Nos. 2,689,848 and 5,668,116 and U.S. Publication No. 2009/0111771.
- the freeze-dried preparation of the present invention freeze-drys an aqueous solution containing 0.25 to 0.75 times (preferably 0.5 times) the concentration of sodium pentosan sulfate and a buffer at the time of reconstitution. This makes it possible to produce a more stable or easily reconstituted preparation.
- the freeze-dried preparation of the present invention contains 25 to 75 mg / mL (preferably, 30 to 70, 40 to 60, or 50 mg / mL) of sodium pentosan sulfate, and 0.55 to 1.65 mg / mL (preferably, Are 0.6-1.6, 0.8-1.4, or 1.1 mg / mL) disodium hydrogen phosphate dodecahydrate, and 1.71-5.13 mg / mL (preferably, (1.8-5.0, 2.0-4.0, or 3.42 mg / mL) by freeze-drying an aqueous solution containing sodium dihydrogen phosphate dihydrate.
- the invention encompasses such aqueous solutions for use in the manufacture of lyophilized formulations.
- the aqueous solution to be used for the production of the lyophilized preparation of the present invention is prepared by dissolving pentosan sodium polysulfate at a concentration of 0.25 to 0.75 times (preferably 0.5 times) at the time of reconstitution and a buffer. It is an aqueous solution containing the agent.
- an aqueous solution for use in the manufacture of the lyophilized formulation of the present invention comprises 25-75 mg / mL (preferably 30-70, 40-60, or 50 mg / mL) sodium pentosan polysulfate, and 0.55- 1.65 mg / mL (preferably, 0.6-1.6, 0.8-1.4, or 1.1 mg / mL) disodium hydrogen phosphate dodecahydrate, and 1.71-5. It contains 13 mg / mL (preferably 1.8 to 5.0, 2.0 to 4.0, or 3.42 mg / mL) of sodium dihydrogen phosphate dihydrate.
- the aqueous solution for use in preparing the lyophilized formulation of the present invention may comprise 25-75 mg / mL (preferably, 30-70, 40-60, or 50 mg / mL) sodium pentosan polysulfate, and 0.22-75 mg / mL.
- 1.65 mg / mL preferably, 0.6 to 1.6, 0.8 to 1.4, or 1.1 mg / mL
- disodium hydrogen phosphate and 1.71 to 5.13 mg / mL
- the composition contains 1.8 to 5.0, 2.0 to 4.0 mg / ml, or 3.42 mg / ml) sodium dihydrogen phosphate dihydrate.
- Freeze-drying can usually include pre-freezing, primary drying, and secondary drying steps. Pre-freezing is usually performed at a temperature below the eutectic point. For example, the preliminary freezing can be performed at a constant temperature, but the temperature can be changed as appropriate. In the present specification, pre-freezing is preferably performed at -40 to -50 ° C for 30 minutes to 3 hours, at -10 to -20 ° C for 1 to 10 hours, and at -40 to -50 ° C for 30 minutes to 3 hours. Can be done in chronological order.
- Primary drying is a process of sublimating frozen water under reduced pressure. It is known that water boils at 0 ° C. in an environment of 610.6 Pa, and the temperature at which it sublimates decreases as the pressure decreases. In the present specification, the primary drying is preferably carried out at 1 to 100 Pa, -10 ° C to -20 ° C, more preferably 2 to 50 Pa, -12 ° C to -18 ° C, most preferably 10 Pa, -14 ° C. Done.
- the primary drying time is not particularly limited as long as the sublimation of the contained water is completed, and may be, for example, 35 to 50 hours or 40 to 45 hours. This may be applied, for example, to the case of 10,000 2.5 mL containing ampules.
- Secondary drying is a dehumidification process that removes residual moisture by raising the temperature at a lower pressure.
- the secondary drying is preferably performed in a full vacuum environment by gradually increasing the temperature.
- the secondary drying may be performed by raising the temperature to 35 to 40 ° C. in a full vacuum environment and then maintaining the temperature at 35 to 40 ° C. for 12 hours.
- the obtained freeze-dried preparation can be sterilized and stable by sealing it with a stopper or an aluminum cap as necessary.
- the freeze-dried preparation has excellent stability required for being supplied as a pharmaceutical.
- the lyophilized formulation herein is stable at 40 ⁇ 2 ° C., 75% RH, known as the accelerated test, for at least 6 months.
- the stability test of pharmaceuticals one month of the accelerated test is considered to be equivalent to six months of storage at normal temperature and normal pressure, and thus the freeze-dried preparation is stable at normal temperature and normal pressure for 36 months.
- the test lyophilized product has such stability is determined by storing the lyophilized product at 40 ⁇ 2 ° C, 75% RH for 6 months, It can be confirmed by analyzing whether the reconstituted solution of the lyophilized product meets the specifications set for the product.
- the formulation after storage meets the specifications, the formulation is determined to be stable for such storage.
- Items in these standards include appearance, clarity and color, average mass, mass uniformity, uniformity of dosage unit, particulate contamination (of reconstituted solution): invisible particulate, (of reconstituted solution)
- Particulate contamination visible particulates, pH value (of reconstituted solution), loss on drying, clarity, phosphate identification, identification of sodium pentosan polysulfate (PPS) by gel permeation chromatography (GPC) and wet chemical analysis , Sodium sulfate purity (IC), purity (GPC), calcium purity, PPS assay (GPC), sterility, and bacterial endotoxin.
- the lyophilized preparation of the present invention can be reconstituted by adding a sterile aqueous diluent, preferably sterile water, and mixing.
- the present invention includes a method for preparing a sodium pentosan polysulfate liquid pharmaceutical composition, comprising reconstituting the lyophilized formulation in a sterile aqueous diluent.
- the concentration of sodium pentosan polysulfate is 80 to 120 mg / mL, preferably 90 to 110 mg / mL, 95 to 105 mg / mL, or 100 mg / mL. Adding a sterile aqueous diluent to the lyophilized formulation such that
- the present invention also encompasses the liquid pharmaceutical composition obtained by the reconstitution.
- the liquid pharmaceutical composition comprises 80-120 mg / mL (preferably 90-110 mg / mL, 95-105 mg / mL, or 100 mg / mL) sodium pentosan polysulfate, 1.6-3. Contains 2 mg / mL disodium hydrogen phosphate dodecahydrate and 3.2-10.4 mg / mL sodium dihydrogen phosphate dihydrate.
- the liquid pharmaceutical composition has a concentration at reconstitution of 100 mg / mL sodium pentosan polysulfate, 2.2 mg / mL disodium hydrogenphosphate decahydrate, and 6.84 mg / mL. Contains sodium dihydrogen phosphate dihydrate. Also, preferably, the pH of the liquid pharmaceutical composition is from 5.0 to 7.0.
- the lyophilized preparation of the present invention or the reconstituted liquid pharmaceutical composition thereof can be used for bovine, deer, horse, donkey, wild boar, pig, sheep, goat, dog, cat, raccoon, fox, rabbit, rat, squirrel and the like. It can be for medical use (for treatment or prevention) for mammals and humans.
- the lyophilized formulation of the present invention may be used as an anticoagulant or for the treatment of interstitial cystitis, osteoarthritis, lysosomal disease, or human lymphotropic virus type 1 (HTLV-1) -associated myelopathy (HAM). It can be a therapeutic or prophylactic agent.
- HTLV-1 human lymphotropic virus type 1
- Lysosomal disease means a disease or disorder caused by accumulation or presence of lysosomal enzymes due to lysosomal enzyme abnormalities.
- Lysosomal diseases include, for example, type II glycogenosis, Pompe disease, ⁇ -glucosidase ⁇ (acid maltase) ⁇ deficiency, sphingolipidosis, GM1 gangliosidosis, GM2 gangliosidosis (Tay-Sachs disease, Sandhoff disease), metachromatic disease Leukodystrophy II (MLD), Fabry disease, Faber disease, Gaucher disease, Niemann-Pick disease (type A, B, C), Krabbe disease, mucopolysaccharidosis, mucolipidosis, multiple sulfatase deficiency (MSD), sialidosis, galacto Including sialidosis, isel disease, ⁇ -mannosidosis, ⁇ -mannosidosis, fucosidosis, aspartyl glucosamineuria, Schindler disease, Wolman disease, Danone disease, free sialic acid storage disease, and celloid lipofuscino
- the present invention comprises administering to a patient in need thereof an effective amount of a liquid pharmaceutical composition obtained by reconstituting a lyophilized formulation of the present invention to a patient in need thereof.
- the present invention relates to a method for treating or preventing arthropathy, lysosomal disease, or HAM.
- "Patient in need thereof” means a patient that is, or is likely to be, affected by these diseases. Preferably, it is a patient suffering from these diseases and in need of treatment.
- the liquid pharmaceutical composition can be administered in an oral dosage form or a parenteral dosage form such as an injection or a drip.
- the dosage varies depending on symptoms, age, sex, body weight, dosage form and the like. For example, when administered orally to an adult, the daily dose per person is usually 100 to 1000 mg.
- Example 1 Production of lyophilized preparation of sodium pentosan polysulfate 33.22 g of disodium hydrogen phosphate dodecahydrate was added to 13.00 kg of water for injection, and then sodium dihydrogen phosphate dihydrate was added to 103.00 kg of water. .28 g were added. 1574.6 g of sodium pentosan polysulfate was added and dissolved in the obtained phosphate buffer, water for injection was added, and the pH was adjusted to 5.9 to 6.1 with 1 mol / L hydrochloric acid and 1 mol / L sodium hydroxide.
- Pre-freezing cooling from room temperature to -42 ° C or lower (about -45 ° C); -42 ° C or lower (about -45 ° C), 1 hour; temperature rise to -14 ° C; -14 ° C, 3 hours; Cooling down to -42 ° C or lower (about -45 ° C); -42 ° C (about -45 ° C) for 1 hour
- Primary drying All under 10 Pa pressure from -42 ° C or lower (about -45 ° C) to 1 hour 30 Temperature rise to -14 ° C over a minute; Secondary drying at -14 ° C for 43 hours: Warm from -14 ° C to 37 ° C under all reduced pressure (full vacuum) conditions; 37 ° C, 12 hours Repressurize with N2 substitution Then, the vial was taken out and sealed with an aluminum cap to obtain a freeze-dried preparation of sodium pentosan polysulfate.
- Example 2 Stability test of freeze-dried preparation of pentosan sodium polysulfate The stability of the freeze-dried preparation of sodium pentosan polysulfate produced by the method of Example 1 was measured at 40 ° C and 75% RH for 6 months. After storage, the stability was evaluated (accelerated test). Table 1 shows the results. The freeze-dried product after storage for 6 months was shown to meet the specifications for all of the evaluation items. In particular, no contamination (visible particles) was observed once during the storage period of 6 months, and it was confirmed that delamination did not occur.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
注射用水13.00kgにリン酸水素二ナトリウム12水和物を33.22g添加し,次いで,リン酸二水素ナトリウム2水和物を103.28g添加した。得られたリン酸緩衝剤にポリ硫酸ペントサンナトリウムを1574.6g添加して溶解させ,注射用水を加えた後,1mol/L塩酸,1mol/L水酸化ナトリウムでpHを5.9~6.1に調節した。全量が31.05kgとなるように注射用水を加えて撹拌し,0.22μmフィルターで滅菌後,バイアル中に2.570g/本となるように充填した。
ゴム栓を半打栓した後,K1凍結乾燥機(DFB-60R-07ASC)を用いて,以下の条件で凍結乾燥を行った。
予備凍結:室温から-42℃以下(約-45℃)まで冷却;-42℃以下(約-45℃),1時間;-14℃まで温度上昇;-14℃,3時間;-14℃から-42℃以下(約-45℃)まで冷却;-42℃(約-45℃),1時間
一次乾燥:全て圧力10Paの条件下で,-42℃以下(約-45℃)から1時間30分かけて-14℃まで温度上昇;-14℃,43時間
二次乾燥:全て減圧(フルバキューム)条件下で,-14℃から37℃まで加温;37℃,12時間
N2置換で復圧した後,バイアルを取り出してアルミキャップでシーリングしてポリ硫酸ペントサンナトリウムの凍結乾燥製剤を得た。
実施例1の方法により製造したポリ硫酸ペントサンナトリウムの凍結乾燥製剤の安定性を40℃,75%RHの条件下で6カ月間保存し,安定性を評価した(加速試験)。
結果を表1に示す。6カ月間保存した後の凍結乾燥製剤は,評価項目の全てについて,規格を満たすことが示された。特に、微粒子混入(目に見える微粒子)については、6カ月間の保存期間中に一度も観察されなかったことから、デラミネーションも起こらないことが確認された。
Claims (20)
- ポリ硫酸ペントサン又はその塩を含有する,凍結乾燥製剤。
- 更に緩衝剤を含有する,請求項1に記載の凍結乾燥製剤。
- 緩衝剤がリン酸緩衝剤である,請求項2に記載の凍結乾燥製剤。
- 凍結保護物質を含有しない,請求項1~請求項3のいずれか1項に記載の凍結乾燥製剤。
- 40±2℃,75%RHにおいて少なくとも6ヶ月間にわたり安定である,請求項1~請求項4のいずれか1項に記載の凍結乾燥製剤。
- 再構成された液体医薬組成物において目に見える微粒子が確認されない,請求項1~請求項5のいずれか1項に記載の凍結乾燥製剤。
- ポリ硫酸ペントサンの塩が、ポリ硫酸ペントサンナトリウムである、請求項1~請求項6のいずれか1項に記載の凍結乾燥製剤。
- 再構成時の前記ポリ硫酸ペントサンナトリウムの濃度が,80~120mg/mLである,請求項7に記載の凍結乾燥製剤。
- 80~120mg/mLのポリ硫酸ペントサンナトリウム,1~4mg/mLのリン酸水素二ナトリウム12水和物,及び4.5~9mg/mLのリン酸二水素ナトリウム二水和物を含有する,請求項7又は請求項8のいずれか1項に記載の凍結乾燥製剤。
- 25~75mg/mLのポリ硫酸ペントサンナトリウムを含有する,ポリ硫酸ペントサンナトリウムの凍結乾燥製剤を調製するための水溶液。
- 更に,0.55~1.65mg/mLのリン酸水素二ナトリウム12水和物,及び1.71~5.13mg/mLのリン酸二水素ナトリウム二水和物を含有する,請求項10に記載の水溶液。
- 請求項10又は請求項11に記載の水溶液を凍結乾燥することを含む,請求項7に記載の凍結乾燥製剤の製造方法。
- 前記凍結乾燥が,-10℃~-20℃で一次乾燥工程を有する,請求項12に記載の製造方法。
- 前記凍結乾燥が,
-40~-50℃を30分~3時間維持すること,
-10~-20℃を1~10時間維持すること,
-40~-50℃を30分~3時間維持すること,
を含む予備凍結工程を有する,請求項12又は請求項13のいずれか1項に記載の製造方法。 - 請求項12~請求項14のいずれか1項に記載の方法により得られた凍結乾燥製剤。
- 間質性膀胱炎,変形性関節症,ライソゾーム病,若しくはHAMの治療剤又は若しくは予防剤,又は,抗凝固剤である,請求項1~請求項9,及び請求項15のいずれか1項に記載の凍結乾燥製剤。
- 請求項1~請求項9,請求項15及び請求項16のいずれか1項に記載の凍結乾燥製剤を再構成することによって得られる,液状医薬組成物。
- 100mg/mLのポリ硫酸ペントサンナトリウムを含有する,請求項17に記載の液状医薬組成物。
- 請求項1~請求項8,請求項15及び請求項16のいずれか1項に記載の凍結乾燥製剤を滅菌水性希釈剤中で再構成することを含む,ポリ硫酸ペントサン又はその塩を含有する液状医薬組成物の調製方法。
- 請求項19の調製方法により調製された液状医薬組成物の有効量をそれを必要とする患者に投与することを含む,間質性膀胱炎,変形性関節症,ライソゾーム病,若しくはHAMの治療方法又は予防方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/269,860 US20210186883A1 (en) | 2018-08-20 | 2018-08-20 | Novel pentosan polysulfate sodium preparation |
EP18931027.9A EP3842048A4 (en) | 2018-08-20 | 2018-08-20 | NOVEL PENTOSAN POLYSULFATE PREPARATION |
PCT/JP2018/030666 WO2020039480A1 (ja) | 2018-08-20 | 2018-08-20 | 新規ポリ硫酸ペントサンナトリウム製剤 |
JP2020537911A JP6935960B2 (ja) | 2018-08-20 | 2018-08-20 | 新規ポリ硫酸ペントサンナトリウム製剤 |
AU2018437600A AU2018437600B2 (en) | 2018-08-20 | 2018-08-20 | Novel pentosan polysulfate sodium preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2018/030666 WO2020039480A1 (ja) | 2018-08-20 | 2018-08-20 | 新規ポリ硫酸ペントサンナトリウム製剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020039480A1 true WO2020039480A1 (ja) | 2020-02-27 |
Family
ID=69591933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/030666 WO2020039480A1 (ja) | 2018-08-20 | 2018-08-20 | 新規ポリ硫酸ペントサンナトリウム製剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210186883A1 (ja) |
EP (1) | EP3842048A4 (ja) |
JP (1) | JP6935960B2 (ja) |
AU (1) | AU2018437600B2 (ja) |
WO (1) | WO2020039480A1 (ja) |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2689848A (en) | 1951-02-06 | 1954-09-21 | Wander Ag Dr A | Salts of sulfuric acid esters of xylan |
US5180715A (en) | 1980-11-17 | 1993-01-19 | The Regents Of The University Of California | Irrigation of internal bladder surfaces in mammals with sodium pentosanpolysulfate |
US5643892A (en) | 1995-06-07 | 1997-07-01 | Baker Norton Pharmaceuticals, Inc. | Method of treating chronic progressive vascular diseases |
US5668116A (en) | 1987-03-19 | 1997-09-16 | Anthropharm Pty. Limited | Anti-inflammatory compounds and compositions |
US20010034328A1 (en) | 2000-02-25 | 2001-10-25 | Cartt Stephen Lahue | Treatment of male chronic pelvic pain syndrome |
WO2008107906A1 (en) | 2007-03-06 | 2008-09-12 | Alembic Limited | Process for the preparation of pentosan polysulfate or salts thereof |
WO2009047699A1 (en) | 2007-10-10 | 2009-04-16 | Alembic Limited | An improved process for the preparation of an amorphous form of pentosan polysulfate or salts thereof |
US20090111771A1 (en) | 2006-09-27 | 2009-04-30 | Sylvan Pharmaceuticals Pty. Ltd. Can 102 641 332 | Inhibition of cathepsin k activity and the treatment and prevention of disease |
WO2009087581A1 (en) | 2008-01-04 | 2009-07-16 | Alembic Limited | An improved process for the preparation of pentosan polysulfate or salts thereof |
JP2009532467A (ja) * | 2006-04-03 | 2009-09-10 | ニュートラマックス ラボラトリーズ,インコーポレイテッド | 安定化ペントサンポリサルフェート(pps)製剤およびその分析方法 |
WO2012101544A1 (en) | 2011-01-29 | 2012-08-02 | Alembic Pharmaceuticals Limited | An improved process for the preparation of pentosan polysulfate or salts thereof |
US9155784B2 (en) | 2011-06-20 | 2015-10-13 | Icahn School Of Medicine At Mount Sinai | Anti-TNF-α therapy for the mucopolysaccharidoses and other lysosomal disorders |
WO2017131130A1 (ja) * | 2016-01-29 | 2017-08-03 | 生化学工業株式会社 | コンドロイチン硫酸及びヒアルロン酸を含有する安定化された水性組成物 |
JP6281659B1 (ja) * | 2017-02-28 | 2018-02-21 | 王子ホールディングス株式会社 | ポリ硫酸ペントサン、医薬組成物及び抗凝固剤 |
WO2018043668A1 (ja) * | 2016-08-31 | 2018-03-08 | 王子ホールディングス株式会社 | ポリ硫酸ペントサンの製造方法 |
JP2018522940A (ja) * | 2015-05-27 | 2018-08-16 | ヴァンガード セラピューティクス, インコーポレイテッド | 鎌状赤血球症の処置のためのペントサンポリ硫酸ナトリウム |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5213788A (en) * | 1988-09-29 | 1993-05-25 | Ranney David F | Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement |
WO2014127418A1 (en) * | 2013-02-20 | 2014-08-28 | The University Of Queensland | Conjugate compound and uses of same |
BR112020004787A2 (pt) * | 2017-09-12 | 2020-09-24 | Oji Holdings Corporation | polissulfato de pentosano, composição farmacêutica, anticoagulante, e, método para produzir polissulfato de pentosano |
-
2018
- 2018-08-20 WO PCT/JP2018/030666 patent/WO2020039480A1/ja active Search and Examination
- 2018-08-20 AU AU2018437600A patent/AU2018437600B2/en active Active
- 2018-08-20 EP EP18931027.9A patent/EP3842048A4/en active Pending
- 2018-08-20 JP JP2020537911A patent/JP6935960B2/ja active Active
- 2018-08-20 US US17/269,860 patent/US20210186883A1/en active Pending
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2689848A (en) | 1951-02-06 | 1954-09-21 | Wander Ag Dr A | Salts of sulfuric acid esters of xylan |
US5180715A (en) | 1980-11-17 | 1993-01-19 | The Regents Of The University Of California | Irrigation of internal bladder surfaces in mammals with sodium pentosanpolysulfate |
US5668116A (en) | 1987-03-19 | 1997-09-16 | Anthropharm Pty. Limited | Anti-inflammatory compounds and compositions |
US5643892A (en) | 1995-06-07 | 1997-07-01 | Baker Norton Pharmaceuticals, Inc. | Method of treating chronic progressive vascular diseases |
US20010034328A1 (en) | 2000-02-25 | 2001-10-25 | Cartt Stephen Lahue | Treatment of male chronic pelvic pain syndrome |
JP2009532467A (ja) * | 2006-04-03 | 2009-09-10 | ニュートラマックス ラボラトリーズ,インコーポレイテッド | 安定化ペントサンポリサルフェート(pps)製剤およびその分析方法 |
US20090111771A1 (en) | 2006-09-27 | 2009-04-30 | Sylvan Pharmaceuticals Pty. Ltd. Can 102 641 332 | Inhibition of cathepsin k activity and the treatment and prevention of disease |
WO2008107906A1 (en) | 2007-03-06 | 2008-09-12 | Alembic Limited | Process for the preparation of pentosan polysulfate or salts thereof |
WO2009047699A1 (en) | 2007-10-10 | 2009-04-16 | Alembic Limited | An improved process for the preparation of an amorphous form of pentosan polysulfate or salts thereof |
WO2009087581A1 (en) | 2008-01-04 | 2009-07-16 | Alembic Limited | An improved process for the preparation of pentosan polysulfate or salts thereof |
WO2012101544A1 (en) | 2011-01-29 | 2012-08-02 | Alembic Pharmaceuticals Limited | An improved process for the preparation of pentosan polysulfate or salts thereof |
US9155784B2 (en) | 2011-06-20 | 2015-10-13 | Icahn School Of Medicine At Mount Sinai | Anti-TNF-α therapy for the mucopolysaccharidoses and other lysosomal disorders |
JP2018522940A (ja) * | 2015-05-27 | 2018-08-16 | ヴァンガード セラピューティクス, インコーポレイテッド | 鎌状赤血球症の処置のためのペントサンポリ硫酸ナトリウム |
WO2017131130A1 (ja) * | 2016-01-29 | 2017-08-03 | 生化学工業株式会社 | コンドロイチン硫酸及びヒアルロン酸を含有する安定化された水性組成物 |
WO2018043668A1 (ja) * | 2016-08-31 | 2018-03-08 | 王子ホールディングス株式会社 | ポリ硫酸ペントサンの製造方法 |
JP6281659B1 (ja) * | 2017-02-28 | 2018-02-21 | 王子ホールディングス株式会社 | ポリ硫酸ペントサン、医薬組成物及び抗凝固剤 |
Non-Patent Citations (6)
Title |
---|
"Merck Index", 1989, MERCK & CO, INC., pages: 7093 |
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19 |
KUMAGAI, KENJI ET AL.: "Clinical Study of Gonarthrosis Using Pentosan Sulfate", THE JOURNAL OF THE JAPANESE ORTHOPAEDIC ASSOCIATION, vol. 81, no. 4, 2007, pages S593, XP009526663, ISSN: 0021-5325 * |
NAKAMURA, TATSUFUMI: "Treatment Outcomes for HTLV-I Associated Myelopathy (HAM)", RINSHO SHINKEIGAKU, vol. 52, no. 12, 1 January 2012 (2012-01-01), pages 1524, XP055790658, DOI: 10.5692/clinicalneurol.52.1397 * |
See also references of EP3842048A4 |
WIJEKOON ET AL., BMC VETERINARY RESEARCH, vol. 14, 2018, pages 152 |
Also Published As
Publication number | Publication date |
---|---|
AU2018437600B2 (en) | 2022-11-17 |
EP3842048A4 (en) | 2022-03-30 |
JP6935960B2 (ja) | 2021-09-15 |
EP3842048A1 (en) | 2021-06-30 |
JPWO2020039480A1 (ja) | 2021-08-10 |
AU2018437600A1 (en) | 2021-04-15 |
US20210186883A1 (en) | 2021-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007322334B2 (en) | Method of drug delivery for bone anabolic protein | |
KR100810872B1 (ko) | 감기 치료용 조성물 | |
AU2020203081A1 (en) | Liquid inhalation formulation comprising RPL554 | |
JPH0430926B2 (ja) | ||
JP4123309B2 (ja) | 鼻内投与のための薬学的非無機塩類液剤 | |
JP2002363097A (ja) | 安定化された凍結乾燥型医薬組成物 | |
US20200316003A1 (en) | Fudosteine Solution Preparation for Aerosol Inhalation, and Preparation Method Therefor | |
JP2010535198A (ja) | コハク酸のコリン塩を含む鼻腔内投与用医薬品組成物 | |
JP7254101B2 (ja) | 複数回使用のトラセミド組成物 | |
JPH04149126A (ja) | 経粘膜投与用医薬組成物 | |
CA1326453C (en) | Pharmaceutical composition containing pentamidine | |
US20200261362A1 (en) | Solution Preparation for Aerosol Inhalation of Carbocisteine, and Preparation Method Therefor | |
JP6935960B2 (ja) | 新規ポリ硫酸ペントサンナトリウム製剤 | |
JP2020147578A (ja) | ハンター症候群を治療するための方法および組成物 | |
EP3381467A1 (en) | Vaccine pharmaceutical composition for oral administration and method for manufacturing vaccine pharmaceutical composition for oral administration | |
RU2737799C1 (ru) | Ингаляционный гексапептид для лечения респираторных заболеваний, связанных с интерлейкином-6 | |
JP6891125B2 (ja) | インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法 | |
SA90110074B1 (ar) | تركيبات صيدلانية متضمنة على محلول مائي من مشتق بيرانوكوينولين pyranoquinoline | |
JP2001187735A (ja) | 安定なニコランジル含有粉末の製造法 | |
WO1987007504A1 (en) | Pharmaceutical composition for the nasal administration of heparin and method for treatment of patients | |
PT93154B (pt) | Processo de preparacao de uma solucao aquosa de um sal de pentamidina e de aerossois compreendendo a referida solucao | |
RU2404797C1 (ru) | КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЧЕЛОВЕЧЕСКИЙ РЕКОМБИНАНТНЫЙ ИНТЕРФЕРОН АЛЬФА-2b, И ЛЕКАРСТВЕННОЕ СРЕДСТВО ПРОЛОНГИРОВАННОГО ДЕЙСТВИЯ ДЛЯ ВЕТЕРИНАРИИ НА ЕЕ ОСНОВЕ, ОБЛАДАЮЩЕЕ ПРОТИВОВИРУСНЫМ И ИММУНОМОДУЛИРУЮЩИМ ДЕЙСТВИЕМ | |
AU2012201490B2 (en) | Method of drug delivery for bone anabolic protein | |
JPS62120321A (ja) | tPA含有医薬組成物 | |
JP2003300908A (ja) | 安定なカルシトニン注射用製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18931027 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2020537911 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018931027 Country of ref document: EP Effective date: 20210322 |
|
ENP | Entry into the national phase |
Ref document number: 2018437600 Country of ref document: AU Date of ref document: 20180820 Kind code of ref document: A |